RANI: Rani Therapeutics Holdings, Inc. Kompaniya qiymatining sof foydaga nisbati

Rani Therapeutics Holdings, Inc. (RANI) korporativ emblemasi va logotipi

Rani Therapeutics (RANI) kompaniyasida Talat Imran boshchiligidagi jamoa biologik moddalarni kapsulalar orqali tashishning innovatsion usullarini ishlab chiqmoqda. Biznes modeli iqtisodiy sikllar yoki mavsumiylikka bog'liq bo'lmay, aksincha, tibbiy maqsadlarga erishishga tayanadi va ushbu ko'rsatkich -1.90 darajasida turibdi. GURU.Markets platformasidagi narxlar tendentsiyasi inyeksiyalarni oral formatga o'tkazish uchun sanoat gigantlari bilan tadqiqot va ishlanmalar (R&D) bo'yicha sheriklik aloqalarini rivojlantirayotgan kompaniyani aks ettirmoqda.

RANI Rani Therapeutics Holdings: Narx-foyda koeffitsiyenti 04.07.2022 - 14.11.2026 oraligʻida

Rani Therapeutics Holdings (RANI) boʻyicha keng qamrovli koʻrsatkichlar kesimi va tahlil

- narx va narxlar bo'yicha konsensus prognoz:
Aksiya narxi Rani Therapeutics Holdings, Inc.|RANI - Konsensus maqsadli narx
- bozor kapitallashuvi haqida ma'lumot:
Bozor qiymati Rani Therapeutics Inc|RANI - Kompaniyaning to‘liq qiymati
- buxgalteriya balansi bo'yicha sof aktivlar qiymati ko'rsatkichlari:
Bitta aksiya hisobiga sof aktivlar qiymati Rani Therapeutics|RANI - Kompaniyaning sof aktivlari|Bozor kapitallashuvining balans qiymatiga multiplikatori ranitherapeutics.com|RANI - Kompaniyaning umumiy aktivlari
- kompaniyaning majburiyatlari va likvidligi ma'lumotlari:
Barcha qarzlarning o‘z mablag‘lariga nisbati Rani Therapeutics|RANI - Uzoq muddatli qarzning kapitalga nisbati|Qisqa muddatli majburiyatlarning kapitalga nisbati ranitherapeutics.com|RANI - Kompaniya qarzlari|Qarzning sof aktivlarga nisbati Rani Therapeutics Inc|RANI - Kompaniyaning uzoq muddatli qarzi|Kompaniyaning qisqa muddatli kredit va qarzlari Rani Therapeutics|Tezkor likvidlik koeffitsiyenti ranitherapeutics.com
- biznes foydasi va investitsiya koeffitsiyentlari ma'lumotlari:
RANI - Kompaniyaning sof foydasi|Sof foyda prognozi Rani Therapeutics|RANI - P/E multiplikatori|Kapitalizatsiyaning prognoz qilingan foydaga nisbati Rani Therapeutics Holdings, Inc.|RANI - Narx-foyda va o‘sish multiplikatori|Biznes qiymatining amortizatsiya chegirilishidan oldingi operatsion foydaga nisbati RANI|RANI - Eskirish chegirilmasdan oldingi operatsion foyda|So'nggi to'rtta chorak uchun bir aksiya uchun foyda Rani Therapeutics|RANI - Bir aksiya uchun sof foyda (EPS TTM)|So'nggi 12 oy davomida bitta aksiya uchun foydaning yillik o'sishi ranitherapeutics.com|RANI - Joriy yilda foyda o'sishi|Keyingi yilda bir aksiya uchun sof foydaning kutilayotgan o'sishi Rani Therapeutics
- emitentning tushumi va sotuvlari tafsilotlari:
RANI - Kompaniya daromadi|Kompaniyaning kelajakdagi daromadi Rani Therapeutics|RANI - P/S multiplikatori|Forvard P/S multiplikatori Rani Therapeutics Inc
Kompaniyaning har tomonlama tahlili:Rani Therapeutics Holdings - RANI
Rani Therapeutics Holdings, Inc. yetakchi tovari

Barqaror aktivlarni spekulyativ instrumentlardan ajratish bozor qiymatining sof foyda nisbatini tahlil qilishni talab etadi, bu esa kelajakdagi o'sish uchun to'langan premiumni baholash imkonini beradi. Rani Therapeutics (RANI) kompaniyasining RaniPill platformasi litsenziyalanishi oldindan to'lovlar kirimini ta'minlaydi va kapitalni mustahkamlaydi; shuning uchun, IFRS P/E ko'paytirgichi biznesning fundamental qiymati va investorlarning pul oqimlarining barqarorligiga oid joriy kutganlari o'rtasidagi muvozanat ko'rsatkichi bo'lib xizmat qiladi.

Raqobatdosh kompaniyalar tahlili

HLN: Kompaniya qiymatining sof foydaga nisbati|Narx-foyda koeffitsiyenti KVUE (Kenvue Corp)|VRNA (Verona Pharma Inc.) - Kompaniya qiymatining sof foydaga nisbati|Narxning foydaga nisbati Jyong Biotech Limited MENS|Ligand (LGND) - Kapitalizatsiyaning foydaga nisbati|AMRX: Narx-foyda koeffitsiyenti|Perrigo - Bozor narxining sof foydaga nisbati|ALVO: P/E multiplikatori|Liquidia Technologies - Kompaniya qiymatining sof foydaga nisbati|GLPG (Galapagos N.V.) - P/E multiplikatori|Kapitalizatsiyaning foydaga nisbati anipharmaceuticals.com ANIP|Narxning foydaga nisbati MannKind (MNKD)|AMPH (Amphastar Pharmaceuticals, Inc.) - Kompaniya qiymatining sof foydaga nisbati|Narxning foydaga nisbati Pacira BioSciences, Inc. PCRX|P/E multiplikatori ARS Corp SPRY|Theravance Biopharma - P/E multiplikatori|Kapitalizatsiyaning sof foydaga nisbati koeffitsiyenti Aquestive Therapeutics, Inc. (AQST)|scPharmaceuticals (SCPH) - Narxning foydaga nisbati|Narx-foyda koeffitsiyenti Tectonic Therapeutic, Inc.|TNXP (Tonix Pharmaceuticals Holding) - P/E multiplikatori|Narx-foyda multiplikatori SXTC (China SXT Pharmaceuticals)|P/E multiplikatori EPRX|P/E multiplikatori bioharvest.com (BHST)|Narxning foydaga nisbati Invizyne Technologies EXOZ|ORMP: Narx-foyda multiplikatori|ENTX: Narx-foyda koeffitsiyenti|HYFT: Narxning foydaga nisbati|ABVC BioPharma Inc. (ABVC) - Narxning foydaga nisbati|cumberlandpharma.com (CPIX) - P/E multiplikatori|QNTM (Quantum BioPharma) - P/E multiplikatori|FGEN: Kompaniya qiymatining sof foydaga nisbati|P/E multiplikatori TELO|SNYR (Synergy CHC) - Kompaniya qiymatining sof foydaga nisbati|Narxning foydaga nisbati Rallybio RLYB|Lexaria Bioscience (LEXX) - Kapitalizatsiyaning foydaga nisbati|PULM - Narxning foydaga nisbati|Biznesning o‘zini qoplash muddati Pheton Holdings PTHL|APM (Aptorum) - Narx-foyda koeffitsiyenti|Lyra Therapeutics, Inc. (LYRA) - P/E multiplikatori|IBO (impactbiomedinc.com) - P/E multiplikatori|TNFA (TNF Pharmaceuticals) - Bozor narxining sof foydaga nisbati|Narxning foydaga nisbati cbdmd.com (YCBD)|Biznesning o‘zini qoplash muddati PainReform Ltd|P/E multiplikatori CYTO (Altamira Therapeutics Ltd.)|Lipella Pharmaceuticals (LIPO) - Kapitalizatsiyaning foydaga nisbati|OPTN - Narxning foydaga nisbati|Pieris Pharmaceuticals - Bozor narxining sof foydaga nisbati|PROC (Procaps Group) - Narx-foyda koeffitsiyenti|PTPI - Biznesning o‘zini qoplash muddati|Narxning foydaga nisbati Qilian International Holding Group Limited|SLRN: Kompaniya qiymatining sof foydaga nisbati|Narx-foyda koeffitsiyenti TFFP (TFF Pharma)